title: Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.
abstract: OBJECTIVE
  Hepatitis B virus reactivation is a serious cause of morbidity and mortality in hepatitis B surface antigen-positive patients treated with chemotherapy. We compared the efficacy of early and deferred preemptive lamivudine therapy in reducing the incidence of hepatitis due to hepatitis B virus reactivation in hepatitis B surface antigen-positive lymphoma patients treated with chemotherapy.
  
  
  METHODS
  Thirty consecutive hepatitis B surface antigen-positive lymphoma patients undergoing intensive chemotherapy were randomized (1:1) to receive lamivudine 100 mg daily 1 week before chemotherapy (group 1) or to have this treatment deferred until there was serological evidence of hepatitis B virus reactivation on the basis of serial 2-week-interval serum hepatitis B virus DNA monitoring by a Digene Hybrid Capture II assay (group 2).
  
  
  RESULTS
  Eight (53%) patients in group 2 and none in group 1 had hepatitis B virus virological reactivation after chemotherapy (P = 0.002). Seven patients in group 2 still had hepatitis (5 anicteric hepatitis, 1 icteric hepatitis, and 1 hepatic failure). Survival free from hepatitis due to hepatitis B virus reactivation in group 1 patients was significantly longer than that in group 2 (P = 0.002 on the log-rank test). The median onset of hepatitis B virus reactivation in these patients was 16 weeks (range, 4-36 weeks) after the initiation of chemotherapy. Three (13%) of the 23 patients treated with lamivudine had hepatitis B virus-related hepatitis after lamivudine withdrawal.
  
  
  CONCLUSIONS
  Lamivudine should be considered preemptively before or at the initiation of chemotherapy for all hepatitis B surface antigen-positive lymphoma patients undergoing intense chemotherapy.
authors.affiliation: Division of Gastroenterology and Hepatology, University Department of Medicine, Queen Mary Hospital, Hong Kong Special Administrative Region, China. gkklau@netvigator.com
authors.forename: George K K
authors.initials: GK
authors.lastname: Lau
authors.forename: Harry H Y
authors.initials: HH
authors.lastname: Yiu
authors.forename: Daniel Y T
authors.initials: DY
authors.lastname: Fong
authors.forename: Hoi-Ching
authors.initials: HC
authors.lastname: Cheng
authors.forename: Wing-Yan
authors.initials: WY
authors.lastname: Au
authors.forename: Lydia S F
authors.initials: LS
authors.lastname: Lai
authors.forename: Micheal
authors.initials: M
authors.lastname: Cheung
authors.forename: Hai-Ying
authors.initials: HY
authors.lastname: Zhang
authors.forename: Albert
authors.initials: A
authors.lastname: Lie
authors.forename: Roger
authors.initials: R
authors.lastname: Ngan
authors.forename: Raymond
authors.initials: R
authors.lastname: Liang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000998:Antiviral Agents / Q000627:therapeutic use*; D004279:DNA, Viral / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000188:drug therapy* / Q000821:virology; D006515:Hepatitis B virus / Q000235:genetics; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D013997:Time Factors; D014775:Virus Activation
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D019259:Lamivudine